ArticleFrontiers in oncology2021

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.

Hui Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.